[ad_1]
OTTAWA – Health Canada says it will suspend licenses for Biocell breast implants unless the company that manufactures them provides new evidence on their safety.
The Department of Health announced that it has conducted a scientific evaluation of macro-texture implants as part of its larger ongoing review of breast implant safety and associated associated cancer, launched in November 2018.
It indicates that anaplastic large cell lymphoma associated with breast implants is a rare type of non-Hodgkin lymphoma, a cancer that affects the immune system, which can develop many months or years after a breast implant procedure.
This is not a cancer of the breast tissue, but usually presents as a build-up of fluid between the implant and the surrounding tissue, and its cause is unknown.
Allergan, the company that makes the implants, did not immediately respond to a request for comment.
Health Canada says that it continues to monitor and review all available scientific and clinical information regarding the safety of textured breast implants, including any new evidence provided by Allergan within the next 15 days.
According to the department, if a satisfactory response is not received by that date, it will suspend licenses for Biocell implants, which means that the products would no longer be allowed to be sold in Canada.
The Canadian press
[ad_2]
Source link